Clinical trial
REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children
NCT00447525 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00447525 |
|---|---|
| Title | REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children |
| Official title | Comparison of the Immunogenicity and Safety of a Combined Adsorbed Low Dose Diphtheria, Tetanus and Inactivated Poliomyelitis Vaccine (REVAXIS®) With a Combined Diphtheria, Tetanus and Inactivated Poliomyelitis Vaccine (DT Polio®) When Given as a Booster Dose at 6 Years of Age |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diphtheria, Tetanus, Poliomyelitis |
| Intervention type | Biological |
| Interventions | REVAXIS®, DT-Polio® |
| Enrollment | 760 |
| Start date | Feb 1, 2007 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Mar 14, 2007 |
| Last update posted | Sep 11, 2017 |
| Countries | France |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: